← Leaderboards
Diane F Jelinek
Mayo Clinic Coll Of Medicine, Rochester
$8,218,570
Attributed
$8,218,570
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$15,717,460 · 12
By mechanism
P01$9,047,145 · 4
R01$5,283,616 · 4
R21$1,113,316 · 3
P50$273,383 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- S Vincent Rajkumar$8,690,866
- Celine M Vachon$17,209,085
- Robert A Kyle$833,522
- Kenneth K Wang$8,863,249
- Joseph A Murray$9,616,112
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaBone MarrowBiologicalGeneticMalignant - DescriptorCellsInsightMalignant NeoplasmsHeterogeneityPlayStagingClinical ResearchNeoplastic CellPlasma CellsCharacteristicsClinicGenesEventMutationB-LymphocytesDisease ProgressionCell LineCell PhysiologyGrowth
Grant awards (45)
Developmental Research Program$129,168
P50 · FY2022 · CA · contact PI
Developmental Research Program$144,215
P50 · FY2021 · CA · contact PI
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression$352,801
R01 · FY2019 · CA · contact PI
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression$363,713
R01 · FY2018 · CA · contact PI
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression$363,713
R01 · FY2017 · CA · contact PI
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression$363,713
R01 · FY2016 · CA · contact PI
Role of lncRNAs in Clinical Heterogeneity of Early Stage IGHV Unmutated CLL$172,913
R21 · FY2016 · CA · contact PI
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression$363,713
R01 · FY2015 · CA · contact PI
Role of lncRNAs in Clinical Heterogeneity of Early Stage IGHV Unmutated CLL$207,495
R21 · FY2015 · CA · contact PI
Role of the BCR in B Cell Chronic Lymphocytic Leukemia$285,880
R01 · FY2013 · CA · contact PI
Metabolic Reprogramming: Essential Role and Early Marker of MGUS Progression$195,045
R21 · FY2013 · CA · contact PI
CD147 Biological Function and Role as a Biomarker of MGUS to Myeloma Progression$193,451
R21 · FY2013 · CA · contact PI
Role of the BCR in B Cell Chronic Lymphocytic Leukemia$304,127
R01 · FY2012 · CA · contact PI
Metabolic Reprogramming: Essential Role and Early Marker of MGUS Progression$172,913
R21 · FY2012 · CA · contact PI
CD147 Biological Function and Role as a Biomarker of MGUS to Myeloma Progression$171,499
R21 · FY2012 · CA · contact PI
Role of the BCR in B Cell Chronic Lymphocytic Leukemia$304,127
R01 · FY2011 · CA · contact PI
Role of the BCR in B Cell Chronic Lymphocytic Leukemia$313,533
R01 · FY2010 · CA · contact PI
Studies on Monoclonal Gammopathies$1,475,669
P01 · FY2009 · CA · contact PI
Role of the BCR in B Cell Chronic Lymphocytic Leukemia$313,533
R01 · FY2009 · CA · contact PI
MECHANISMS OF CELL MYELOMA CELL GROWTH CONTROL$283,620
P01 · FY2009 · CA · contact PI
ADMINISTRATIVE$49,254
P01 · FY2009 · CA · contact PI
Studies on Monoclonal Gammopathies$1,439,826
P01 · FY2008 · CA · contact PI
role of BLyS/April in Normal and Malignant Plasma Cells$258,035
R01 · FY2008 · CA · contact PI
MECHANISMS OF CELL MYELOMA CELL GROWTH CONTROL$217,448
P01 · FY2008 · CA · contact PI
ADMINISTRATIVE$37,761
P01 · FY2008 · CA · contact PI
Studies on Monoclonal Gammopathies$1,422,984
P01 · FY2007 · CA · contact PI
role of BLyS/April in Normal and Malignant Plasma Cells$258,035
R01 · FY2007 · CA · contact PI
MECHANISMS OF CELL MYELOMA CELL GROWTH CONTROL$211,115
P01 · FY2007 · CA · contact PI
ADMINISTRATIVE$36,662
P01 · FY2007 · CA · contact PI
Studies on Monoclonal Gammopathies$1,463,958
P01 · FY2006 · CA · contact PI
role of BLyS/April in Normal and Malignant Plasma Cells$265,742
R01 · FY2006 · CA · contact PI
MECHANISMS OF CELL MYELOMA CELL GROWTH CONTROL$204,964
P01 · FY2006 · CA · contact PI
ADMINISTRATIVE$35,594
P01 · FY2006 · CA · contact PI
Studies on Monoclonal Gammopathies$1,491,070
P01 · FY2005 · CA
role of BLyS/April in Normal and Malignant Plasma Cells$272,138
R01 · FY2005 · CA
MECHANISMS OF CELL MYELOMA CELL GROWTH CONTROL$208,880
P01 · FY2005 · CA
ADMINISTRATIVE$34,556
P01 · FY2005 · CA
role of BLyS/April in Normal and Malignant Plasma Cells$272,138
R01 · FY2004 · CA
MONOCLONAL GAMMOPATHIES$205,383
P01 · FY2004 · CA
MECHANISMS OF MYELOMA CELL GROWTH CONTROL$228,401
P01 · FY2002 · CA
MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA$215,189
R01 · FY2002 · CA
MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA$209,504
R01 · FY2001 · CA
MECHANISMS OF MYELOMA CELL GROWTH CONTROL$0
P01 · FY2001 · CA
MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA$203,982
R01 · FY2000 · CA
MECHANISMS OF MYELOMA CELL GROWTH CONTROL$0
P01 · FY2000 · CA